

ISSUE @ A GLANCE

-  Controversies in hypertension management: target blood pressure, renal nerve ablation, ARNIs, and NSAIDs medication
T.F. Lüscher

3245

CardioPulse

- Finn Waagstein MD PhD
M. Nicholls 3249
- New Twitter Editor, European Society of Cardiology Journals 3250
- European Heart Journal - Cardiovascular Pharmacotherapy
S. Agewall 3251
- ESC CardioMed
A. Tofield 3252
- David Wood MD FRCP FESC
M. Nicholls 3253
- Ferrara I: Introduction
R. Ferrari 3255


CURRENT OPINION

- Hypertension
From 'essential' hypertension to intensive blood pressure lowering: the pros and cons of lower target values
T.F. Lüscher, S.E. Kjeldsen, G. Mancia, and V. Papademetriou 3258

- Prevention and epidemiology
Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future
F. Mahfoud, R.E. Schmieder, M. Azizi, A. Pathak, H. Sievert, C. Tsiofis, T. Zeller, S. Bertog, P.J. Blankenstijn, M. Böhm, M. Burnier, G. Chatellier, I. Durand Zaleski, S. Ewen, G. Grassi, M. Joner, S.E. Kjeldsen, M.D. Lobo, C. Lotan, T.F. Lüscher, G. Parati, P. Rossignol, L. Ruilope, F. Sharif, E. van Leeuwen, M. Volpe, S. Windecker, A. Witkowski, and W. Wijns 3272

FAST TRACK CLINICAL RESEARCH

Hypertension



Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial

F. Ruschitzka, J.S. Borer, H. Krum, A.J. Flammer, N.D. Yeomans, P. Libby, T.F. Lüscher, D.H. Solomon, M.E. Husni, D.Y. Graham, D.A. Davey, L.M. Wisniewski, V. Menon, R. Fayyad, B. Beckerman, D. Iorga, A.M. Lincoff, and S.E. Nissen; on behalf of the PRECISION-ABPM Investigators

3282

Editorial

Safety of non-steroidal anti-inflammatory drugs

W.S. Weintraub

3293

CLINICAL RESEARCH**Hypertension**

Office blood pressure or ambulatory blood pressure for the prediction of cardiovascular events

3296


R.N. Mortensen, T.A. Gerdts, J.L. Jeppesen, and C. Torp-Pedersen

Editorial

Improving Cardiovascular Risk Prediction: A Tale of Sisyphus

3305

M.L. De Buyzere and T.C. Gillebert



The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study
R.E. Schmieder, F. Wagner, M. Mayr, C. Delles, C. Ott, C. Keicher, M. Hrabak-Paar, T. Heye, S. Aichner, Y. Khder, D. Yates, D. Albrecht, T. Langenickel, P. Freyhardt, R. Janka, and J. Bremerich

3308

Editorial

Advantages of sacubitril/valsartan beyond blood pressure control in arterial hypertension

3318

G. Ruiz-Hurtado and L.M. Ruilope

VIEWPOINT

Renal denervation: will the Phoenix rise from the ashes?

3321

F.H. Messerli and S. Bangalore

CARDIOVASCULAR FLASHLIGHTS

Ruptured oesophageal haematoma caused by transoesophageal echocardiography

E. Pedzich-Placha, A. Rdzanek, J. Kochman, and Z. Huczek

3324

Cactus aorta

A. Mahrouf, G. Soulat, D. Lebeaux, L. Iserin, and C. Karsenty


3325



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site

<https://academic.oup.com/eurheartj>



www.eurheartj.org